AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05366166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: In the induction phase, participants will receive a single intravenous infusion of pembrolizumab 400 mg prior to chemoradiotherapy. In the Maintenance Phase, participants will receive pembrolizumab 400 mg every 42 days for 8 cycles.
Study NCT05366166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: In the induction phase, participants will receive daily oral olaparib 150 mg two times a day for 3 weeks prior to chemoradiotherapy. In the Maintenance Phase, participants will receive daily olaparib 150 mg two times a day for up to 48 weeks.
Study NCT05366166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: In the chemoradiation phase, participants will receive weekly intravenous cisplatin infusion, 40 mg/m2 over 7 weeks.~In the chemoradiation phase, standard of care radiation therapy and chemotherapy will be administered, for a total of 7 weeks. Radiation therapy is done on daily basis (excluding weekends), and chemotherapy therapy will involve cisplatin infusion once weekly.
Study NCT05366166 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT (intensity modulated radiation therapy)
Description: In the chemoradiation phase, participants will receive 70 Gray external beam radiotherapy, at 2 Gray/fraction dose, 35 fractions, delivered once a day, on weekdays, using Intensity Modulated Radiotherapy Treatments or proton radiotherapy techniques, over 7 weeks.
Study NCT06402019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)
Description: Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
Study NCT06402019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group went under multiple sessions of normal saline injection.
Study NCT05791617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cardiac PET/MRI
Description: Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
Study NCT05791617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Study NCT05791617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: NT-proBNP
Description: NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Study NCT05939687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesh
Description: We'll use mesh repair for prevention of stoma-site hernias in the study group.
Study NCT05939687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-mesh
Description: We'll use the layered ligature suturing of the abdominal wall without mesh implantation in the control group.
Study NCT05686577 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05444816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised Neurofeedback training at home
Description: The already available Brain Hero® EEG device will be mailed to the subject's home, along with clear video instructions regarding its use (within the app), as previously established in a beta usability study with optimal results.~All game training will take place at home, while the caregivers of patients will receive instructions either online or telephonically from the investigating team. The team is also ready with tips and tricks to keep the child motivated and facilitate the flight of the game hero in the direction of interest.~Patients will be instructed to play a minimum of 20 min for four times a week, under supervision by their caregiver(s). Patients will be provided with a training plan, including all planned months of training and advanced examinations. Instructions will also be provided, verbally and written, and the investigating team will engage in video sessions or direct meetings with the parents to make sure all instructions are properly followed.
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO]
Description: For the induction of anesthesia, patients allocated to the remimazolam group will receive intravenous infusion of remimazolam at a rate of 6 mg/kg/h, followed by 1 mg/kg/h after the loss of consciousness. The infusion rate of remimazolam will be adjusted to a maximum rate of 2 mg/kg/h to achieve a bispectral index of 40 to 60.
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For the induction of anesthesia, patients allocated to the propofol group will receive a bolus dose of propofol 1.5 mg/kg. After the loss of consciousness, general anesthesia will be maintained with sevoflurane to achieve a bispectral index of 40 to 60.
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After the loss of consciousness, a bolus of rocuronium 1 mg/kg was intravenously administered. After 90 seconds of manual ventilation, endotracheal intubation was performed
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
Study NCT05423951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: During the study period, a total dose of sufentanil 0.5-2.0 mcg/kg was intravenously administered at the attending anesthesiologists' discretion.
Study NCT05595135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive interactive text messaging.
Study NCT05595135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive medication reminders via smart pill bottle
Study NCT05595135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05595135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05070585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isothiocyanate rich sprouts
Description: Isothiocyanate rich sprout juice consumption for 1 week
Study NCT05070585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Juice
Description: Sprout juice devoid of isothiocyanates for 1 week
Study NCT05138354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: MLS® device (ASA Srl, Vicenza, Italy) IR laser with two synchronized sources (laser diodes) and a wavelength of 808 nm to deliver the intervention. The laser probe will be held vertically in contact with the skin to deliver the irradiation at three mandibular condyle points (front, behind and over) and one point at the external acoustic meatus. The irradiation will be applied with a laser bean of 3.14 cm² diameter for 14 seconds at each place using a pulse rate of 1500 Hz, pulse duration of 100ns, and energy density: 16 J/cm².
Study NCT05138354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Patients will be positioned in supine in a treatment table. The therapist seated beside the patient at the side of affected temporomandibular joint to apply gross release technique for masseter, pterygoid and temporalis muscles. At each point, the therapist applied the technique for 90 seconds and repeated 5 times during the session (5 seconds of rest between each repetition).(15) The therapist worn gloves to deliver the intraoral myofascial release. In case the patient reported any latex allergies, the gloves were replaced by a latex free model.
Study NCT05138354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: 1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles.
Study NCT05138354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: 1. Ultrasound Participants will receive an application of pulsed ultrasound at a frequency of 3 MHz and an intensity of 0.5 W/cm² with a 1:1 duty cycle over TMJ for six minutes.~2. Hot pack Participants will receive a warm water pack the TMJ and masticatory muscles for 10 minutes.~3. Exercise program:~Active exercises for mandibular muscles will be used to correct the mouth opening~1. Lateral movements of the jaw (3 sets of 10 repetitions).~2. Jaw relaxation exercise (3 sets of 10 repetitions).~3. Chin tuck (10 repetitions, holding 10s each).~4. Resisted opening of the mouth (3 sets of 10 repetitions).~5. Resisted closing of the mouth (3 sets of 10 repetitions).~6. Stretching exercise for mandibular muscles.
Study NCT04771910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical cream with live probiotic bacteria
Description: Application of the probiotic cream once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as placebo cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
Study NCT04771910 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Application of the placebo cream (same formulation as probiotic cream except live probiotic bacteria) once a day, for approximately 8 weeks on one side of the body (elbow or knee cavity; decided by doctor in advance, same as probiotic cream). Assessment before product use (T0), after 4 and 8 weeks of product use (T4w and T8w, respectively) and after 4 weeks without product use (T12w).
Study NCT04074811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
Study NCT04074811 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The investigators will use the Figure of 8 coil, which affects \~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
Study NCT05227248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Patients were administered 20 grams of dark chocolate
Study NCT05227248 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Chocolate
Description: Patients were administered 7.5 grams of milk chocolate
Study NCT06415539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physical therapy program
Description: Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.
Study NCT06415539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical physical therapy program
Description: Children in the control group, where classical physiotherapy and rehabilitation methods are applied, will continue their individual training programs with a physiotherapist for 40 minutes, 2 days a week, for 8 weeks.
Study NCT06415539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Children in this group will be given vestibular and proprioceptive exercise training in addition to the classical physiotherapy program. Skateboard, swing, hammock, bowl, ball, sensory pads, ball pool, slide, climbing bar, trampoline and balance board will be used as materials in vestibular and proprioceptive exercise training. In addition, at the end of the training sessions, parents will be informed about the application of exercise training to daily activities.
Study NCT04571840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multiparametric MRI +/- prostate biopsy
Description: MRI with T2-weighted, diffusion weighted and dynamic contrast enhanced sequences followed by prostate biopsy if indicated on MRI and clinical findings
Study NCT04571840 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biparametric MRI +/- prostate biopsy
Description: MRI with T2-weighted and diffusion weighted sequences followed by prostate biopsy if indicated on MRI and clinical findings
Study NCT06139848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Conventional therapy include heating therapy for 10 mints, Bridging exercises (10 rep, 3 sets), Paraspinal muscle stretch.
Study NCT06139848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior-anterior spinal mobilization, prone press up Techniques
Description: Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions.
Study NCT06139848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior-anterior spinal mobilization, prone press up Techniques
Description: Posterior-anterior spinal mobilization and prone press- ups techniques. Posterior- Anterior glides and prone press up along with conventional therapy. PA Mobilization on lumber spine, grade I if patient feel no pain the therapist will proceed to grade III-IV. 3 sets for 40 seconds. Total time 10 mints.~Prone press-ups will be performed actively by the patients without no reproduction of pain with lumber extension in standing. In prone press-up the patient pelvis stabilized in prone position and asked for active extension. End range time 5 seconds. Total 10 repetitions.
Study NCT04844320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cobb angle measurements
Description: PA Chest x-rays will be taken in all patients in the preoperative, postoperative 1st year and 2nd year
Study NCT06017245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: whole-body vibration to Control
Description: Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
Study NCT06017245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration to Control
Description: Whole-body vibration (WBV) will be applied while standing upright. During this position, he will be asked not to voluntarily contract the calf muscles and to remain relaxed. The vibration will be applied with the PowerPlate® Pro5 WBV (London UK) device. The vibration amplitude will be 2 mm. The vibration frequency will be 30, 33, and 36 Hz. Each vibration frequency will be applied for 45 seconds. A 5-second rest period will be applied between vibrations of 45 seconds.
Study NCT04850651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib；Fluconazole
Description: Drug: Pyrotinib Participants received a single oral dose of Pyrotinib tablet on the morning of day1 in treatment period 1.~Drug: Pyrotinib/Fluconazole In treatment period 2, Participants received a single oral dose of pyrotinib tablet on the morning of day9, and received a loading dose of fluconazole capsule on day6 followed by single dose of fluconazole for oral administration from D7 to D18.
Study NCT06188117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 'Digital Game Addiction Awareness Training'
Description: Experimental Group The 'Digital Game Addiction Awareness Training' program will be implemented in 2 sessions in 1 day for a total of 2 hours.~The training program will be implemented in line with the headings 'Digital Game Addiction Definition, Diagnostic Criteria, Frequency, Symptoms, Physical, Psychological and Social Problems Caused by Excessive Digital Game Playing, Recommendations for Parents to Prevent Digital Game Addiction'.
Study NCT06032806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moderate intensity
Description: * Arm circles~* Leg swings~* Lunges
Study NCT06032806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity
Description: * Arm circles~* Leg swings~* Lunges~* Butt kicks
Study NCT05383378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: si-544
Description: Subcutaneous injection in the abdomen
Study NCT05383378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection in the abdomen
Study NCT06389617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone
Description: Comparing the onset of sensory, motor block, duration of motor block and analgesic duration
Study NCT05283434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica
Description: Patients will be assigned to the placebo (e.g., unmedicated sugar pill) or experimental group (e.g., Arnica 1M pellets) via a randomization chart from that only the research pharmacist will have access to. Subjects assigned to the experimental group will take the recommended doses of Arnica 1M coated sugar pellets (i.e., 2 pills to be taken every 4 waking hours over a 24 hours period), and will track their pain scores, swelling measurements, sleep rate, ibuprofen doses, adverse reactions, further ED visits, and the number of days/activities the patient has missed for 3 days following their enrollment in the study.
Study NCT05283434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill placebo
Study NCT05403645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Movement With Mobilization
Description: with the help of Movement With Mobilization technique
Study NCT05403645 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: with the help of Exercise Therapy technique
Study NCT05126316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG09222
Description: Lu AG09222 will be administered per schedule specified in the arm description.
Study NCT05126316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to Lu AG09222 will be administered per schedule specified in the arm description.
Study NCT04609514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Learn to Quit-HIV
Description: A smartphone app developed by the research team designed for people with HIV that provides Acceptance and Commitment Therapy skills to address smoking cessation.
Study NCT04609514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
Study NCT04609514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.
Study NCT04609514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: All participants will receive an 8-week course of nicotine patches. They will start off with 4 weeks of 21mg/24 hours patches, then move to 2 weeks of 14mg/24 hours patches, and finally end with 2 weeks of 7mg/24 hours patches.